Artigo de periodico

PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells (2019)

• Authors:
  • Vidotto, Thiago
  • Saggioro, Fabiano Pinto
  • Jamaspishvili, Tamara
  • Chesca, Deise Lúcia
  • Albuquerque, Clarissa Gondim Picanço de
  • Reis, Rodolfo Borges dos
  • Graham, Charles H.
  • Berman, David M.
  • Siemens, D. Robert
  • Squire, Jeremy Andrew
  • Koti, Madhuri
• USP affiliated authors: SAGGIORO, FABIANO PINTO - SVOI ; CHESCA, DEISE LUCIA - FMRP ; REIS, RODOLFO BORGES DOS - FMRP ; SQUIRE, JEREMY ANDREW - FMRP ; VIDOTTO, THIAGO - FMRP ; ALBUQUERQUE, CLARISSA GONDIM PICANÇO DE - FMRP
• Unidades: SVOI; FMRP
• DOI: 10.1002/pros.23808
• Subjects: PRÓSTATA; NEOPLASIAS; SISTEMA IMUNE; REGULAÇÃO GÊNICA
• Keywords: IDO1; Immune checkpoint; Prostate cancer; PTEN; T regulatory cell; Tumor microenvironment
• Agências de fomento:
  • Financiado pelo Prostate Cancer Canada
  • Financiado pela Movember Foundation
  • Financiado pela Transformative Pathology Fellowship funded by the Ontario Institute for Cancer Research (OICR)
  • Financiado pela FAPESP
• Language: Inglês
• Imprenta:
  • Publisher place: Hoboken
  • Date published: 2019
• Source:
  • Título: The Prostate
  • ISSN: 0270-4137
  • Volume/Número/Paginação/Ano: v. 79, n. 9, p. 969-979, 2019


Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).

Status:

Artigo possui versão em acesso aberto em repositório (Green Open Access)

Versão do Documento:

Versão publicada (Published version)

Acessar versão aberta:

• URL de acesso aberto
• PDF de acesso aberto

Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.

---

Download do texto completo

Tipo	Nome	Link
	002979769.pdf

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  VIDOTTO, Thiago et al. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. The Prostate, v. 79, n. 9, p. 969-979, 2019Tradução . . Disponível em: https://doi.org/10.1002/pros.23808. Acesso em: 15 abr. 2026.

• APA

  Vidotto, T., Saggioro, F. P., Jamaspishvili, T., Chesca, D. L., Albuquerque, C. G. P. de, Reis, R. B. dos, et al. (2019). PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. The Prostate, 79( 9), 969-979. doi:10.1002/pros.23808

• NLM

  Vidotto T, Saggioro FP, Jamaspishvili T, Chesca DL, Albuquerque CGP de, Reis RB dos, Graham CH, Berman DM, Siemens DR, Squire JA, Koti M. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells [Internet]. The Prostate. 2019 ; 79( 9): 969-979.[citado 2026 abr. 15 ] Available from: https://doi.org/10.1002/pros.23808

• Vancouver

  Vidotto T, Saggioro FP, Jamaspishvili T, Chesca DL, Albuquerque CGP de, Reis RB dos, Graham CH, Berman DM, Siemens DR, Squire JA, Koti M. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells [Internet]. The Prostate. 2019 ; 79( 9): 969-979.[citado 2026 abr. 15 ] Available from: https://doi.org/10.1002/pros.23808

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features
• Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
• PTEN loss associates with STAT1/3 expression and intra-tumoral CD8+ density in prostate cancer
• Quantitative measurement of PTEN loss improves risk assessment in prostate cancer
• Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
• Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy
• Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer
• Investigating the role of SNAI1 and ZEB1 expression in prostate cancer progression and immune modulation of the tumor microenvironment
• Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics
• Characterization of PTEN gene as a prognostic biomarker in prostate cancer